임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
29건 표시
- 3상모집 중단 (진행 중)· Obesity DiseaseEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
리드: 암젠
- 3상모집 중단 (진행 중)· Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
리드: 암젠
- 3상모집 중단 (진행 중)· Relapsing-remitting Multiple Sclerosis (RRMS)Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
리드: 암젠
- 3상모집 중단 (진행 중)· Metastatic Castration-resistant Prostate CancerPhase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
리드: 암젠
- 3상모집 중단 (진행 중)· Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
리드: 암젠
- 3상모집 중단 (진행 중)· Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerA Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
리드: 암젠
- 3상모집 중단 (진행 중)· Prurigo NodularisA Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
리드: 암젠
- 3상모집 중단 (진행 중)· Extensive-Stage Small-Cell Lung CancerStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
리드: 암젠
- 3상모집 중단 (진행 중)· Osteogenesis ImperfectaStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
리드: 암젠
- 3상모집 중단 (진행 중)· Sjögren's Syndrome (SS)A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
리드: 암젠
- 3상모집 중단 (진행 중)· Limited Stage Small Cell Lung CancerStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
리드: 암젠
- 3상모집 중단 (진행 중)· Plaque PsoriasisA Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
리드: 암젠
- 3상모집 중단 (진행 중)· Small Cell Lung Cancer (SCLC)Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
리드: 암젠
- 3상모집 중단 (진행 중)· Plaque PsoriasisA Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
리드: 암젠
- 3상모집 중단 (진행 중)· Atherosclerotic Cardiovascular DiseaseOlpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
리드: 암젠
- 3상모집 중단 (진행 중)· Eosinophilic EsophagitisEfficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
리드: 아스트라제네카 · 협력: 암젠
- 3상모집 중단 (진행 중)· Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
리드: 암젠
- 3상모집 중단 (진행 중)· IgG4 Related DiseaseA Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
리드: 암젠
- 3상모집 중단 (진행 중)· Multiple MyelomaIsa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
협력: 암젠, 사노피
- 3상모집 중단 (진행 중)· KRAS p, G12c Mutated /Advanced Metastatic NSCLCStudy to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
리드: 암젠
- 3상모집 중단 (진행 중)· Chemotherapy-induced ThrombocytopeniaStudy of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
리드: 암젠
- 3상모집 중단 (진행 중)· MigraineEfficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
리드: 암젠 · 협력: 노바티스
- 3상모집 중단 (진행 중)· Colorectal CancerStudy to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
협력: 암젠
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.